ALLR
ALLR clinical trials: Allarity Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Allarity Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALLR on the catalyst calendar · ALLR registry changes
- Primary completion Jun 2027Sponsor estimateNo phase registeredNCT03877796Clinical Pre-screening Protocol for Ovarian CancerAllarity Therapeutics · Ovarian CancerRecruitingALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2024ActualPhase 1NCT05571969Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsAllarity Therapeutics · Advanced Solid TumorsTerminatedALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2024ActualPhase 2NCT04796324Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.Allarity Therapeutics · Metastatic Breast CancerTerminatedALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT03878849Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerAllarity Therapeutics · Advanced Ovarian CancerRecruitingALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2021ActualPhase 2NCT03643107Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)Allarity Therapeutics · Metastatic Castration-Resistant Prostate Cancer PatientsCompletedALLRLeadLTRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2024ActualPhase 2NCT03562832Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by...Allarity Therapeutics · Metastatic Breast CancerCompletedALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2021ActualPhase 1/Phase 2NCT01861496Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory TumoursAllarity Therapeutics · Phase 1: Advanced or Refractory Solid TumoursCompletedALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2020ActualPhase 1/Phase 2NCT03196947Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRPAllarity Therapeutics · Relapsed/Refractory Multiple MyelomaTerminatedALLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner